HOUSTON, TEXAS (April 30, 2018) – Procyrion, Inc., a clinical-stage medical device company developing the first catheter-deployed, intra-aortic pump for ambulatory use, Aortix™, announced today the appointment of Tara Burt as Associate Director of Clinical Affairs. Burt’s knowledge of clinical strategy, trial execution and operations will be a commanding asset to Procyrion as it continues to advance its intra-aortic heart pump for use in NYHA Class III-IVa heart failure patients.
Burt will devise and execute the clinical trial strategy, including identification of new clinical centers and geographies and manage all aspects of conducting the clinical studies.
“We’re pleased to welcome Tara to the Procyrion team,” said Ben Hertzog, Chief Executive Officer of Procyrion. “Tara’s knowledge and leadership in running pivotal clinical programs is the perfect mix of expertise that will be vital to us as we move through clinical trials and beneficial to the success of Procyrion.”
Procyrion’s technology, Aortix™, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically for the ambulatory treatment of NYHA Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions like heart transplants or LVAD implants. Once placed and operating in the thoracic aorta, the small but powerful micro pump is placed downstream of the heart in a simple cath-lab procedure and works to support heart function by accelerating native blood flow, providing benefit upstream and downstream.
Prior to joining Procyrion, Ms. Burt was Clinical Program Manager, at Medtronic, where she managed the clinical research program, new product development activities, designed clinical studies and oversaw the clinical research team for the Interventional Lung Solutions business. Prior to Medtronic, Ms. Burt held positions with both medical device and biopharma companies, where she executed clinical trials that resulted in global market clearances and approvals.
Burt holds a BA from the University of Rochester and received her Certificate in Premedical Sciences from Columbia University.
Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use. The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients. For more information, visit www.procyrion.com or call 713.579.9227.